Cannabis extracts and methods of preparing and using same

{
  "publication_number": "US9730911B2",
  "country": "US",
  "kind": "B2",
  "title": "Cannabis extracts and methods of preparing and using same",
  "abstract": "The invention relates to the extraction of pharmaceutically active components from plant materials, and more particularly to the preparation of a botanical drug substance (BDS) for incorporation in to a medicament. It also relates to a BDS, for use in pharmaceutical formulations. In particular it relates to BDS comprising cannabinoids obtained by extraction from cannabis.",
  "claims": [
    "1. A liquid cannabinoid formulation, wherein at least 95% of the total cannabinoids is tetrahydrocannabinolic acid (THCa).",
    "2. The formulation of claim 1, further comprising at least one terpene/flavonoid.",
    "3. The formulation of claim 2, wherein the terpene/flavonoid is d-limonene linalool, 1,8-cineole (eucalyptol), α-pinene, terpineol-4-ol, p-cymene, borneol, Δ-3-carene, β-sitosterol, β-myrcene, β-caryophyllene, cannflavin A, apigenin, quercetin or pulegone.",
    "4. The formulation of claim 2, wherein the formulation comprises no more than 4% terpene.",
    "5. A liquid cannabinoid formulation, wherein at least 95% of the total cannabinoids is tetrahydrocannabinol (THC).",
    "6. The formulation-of claim 5, further comprising at least one terpene/flavonoid.",
    "7. The formulation of claim 5, wherein the formulation comprises no more than 4% terpene.",
    "8. The formulation of claim 6, wherein the terpene/flavonoid is d-limonene linalool, 1,8-cineole (eucalyptol), α-pinene, terpineol-4-ol, p-cymene, borneol, Δ-3-carene, β-sitosterol, β-myrcene, β-caryophyllene, cannflavin A, apigenin, quercetin or pulegone.",
    "9. The formulation of claim 1 or 5, wherein the formulation comprises no more than 4% terpene, wherein said terpene comprises myrcene, caryophyllene, and limonene.",
    "10. A liquid cannabinoid formulation, wherein at least 95% of the total cannabinoids is cannabidiol (CBD).",
    "11. The formulation of claim 10, wherein the formulation further comprises less than 1% THC.",
    "12. The formulation-of claim 10, further comprising at least one terpene/flavonoid.",
    "13. The formulation of claim 10, wherein the formulation comprises no more than 4% terpene.",
    "14. The formulation of claim 12, wherein the terpene/flavonoid is d-limonene linalool, 1,8-cineole (eucalyptol), α-pinene, terpineol-4-ol, p-cymene, borneol, Δ-3-carene, β-sitosterol, β-myrcene, β-caryophyllene, cannflavin A, apigenin, quercetin or pulegone.",
    "15. The formulation of claim 10, wherein the formulation comprises no more than 4% terpene, wherein said terpene comprises myrcene, caryophyllene, and limonene.",
    "16. A liquid cannabinoid formulation, wherein at least 95% of the total cannabinoids is THCa and cannabidiolic acid (CBDa).",
    "17. The formulation-of claim 16, further comprising at least one terpene/flavonoid.",
    "18. The formulation of claim 16, wherein the formulation comprises no more than 4% terpene.",
    "19. The formulation of claim 17, wherein the terpene/flavonoid is d-limonene linalool, 1,8-cineole (eucalyptol), α-pinene, terpineol-4-ol, p-cymene, borneol, Δ-3-carene, β-sitosterol, β-myrcene, β-caryophyllene, cannflavin A, apigenin, quercetin or pulegone.",
    "20. A liquid cannabinoid formulation, wherein at least 95% of the total cannabinoids are THC and CBD.",
    "21. The formulation-of claim 20, further comprising at least one terpene/flavonoid.",
    "22. The formulation of claim 20, wherein the formulation comprises no more than 4% terpene.",
    "23. The formulation of claim 21, wherein the terpene/flavonoid is d-limonene linalool, 1,8-cineole (eucalyptol), α-pinene, terpineol-4-ol, p-cymene, borneol, Δ-3-carene, β-sitosterol, β-myrcene, β-caryophyllene, cannflavin A, apigenin, quercetin or pulegone.",
    "24. The formulation of claim 16 or 20, wherein the formulation comprises no more than 4% terpene, wherein said terpene comprises myrcene, limonene, pinene, and caryophyllene.",
    "25. A liquid cannabinoid formulation, wherein at least 95% of the total cannabinoids are CBD, cannabinol (CBN) and THC.",
    "26. The formulation of claim 25, wherein the formulation comprises less than 9% THC.",
    "27. The formulation-of claim 25, further comprising at least one terpene/flavonoid.",
    "28. The formulation of claim 25, wherein the formulation comprises no more than 4% terpene.",
    "29. The formulation of claim 27, wherein the terpene/flavonoid is d-limonene linalool, 1,8-cineole (eucalyptol), α-pinene, terpineol-4-ol, p-cymene, borneol, Δ-3-carene, β-sitosterol, β-myrcene, β-caryophyllene, cannflavin A, apigenin, quercetin or pulegone.",
    "30. The formulation of claim 25, wherein the formulation comprises no more than 4% terpene, wherein said terpene comprises myrcene, pinene and caryophyllene.",
    "31. The formulation of any one of the proceeding claims, wherein the formulation is infused in a medium chain triglyceride (MCT).",
    "32. The formulation of claim 31, wherein the MCT is NEOBEE 895.",
    "33. The formulation of claim 1, 5, 10, 16, 20, or 25, formulated for oral, sublingual, buccal, or topical administration.",
    "34. The formulation of claim 33, wherein the sublingual formulation further comprises a sweetener.",
    "35. The formulation of claim 34, wherein the sweetener is a stevia extract.",
    "36. The formulation of claim 34, further comprising lemon oil, orange oil or both."
  ],
  "description_excerpt": "This invention relates to the extraction of pharmaceutically active components from plant materials, and more particularly to botanical drug substance (BDS) comprising cannabinoids obtained by extraction from cannabis. Methods of using the extracts to treat chronic pain, paralysis, neuropathy, Crohn's Disease, IBS, glaucoma, PTSD, anxiety, seizures, epilepsy, autoimmune disorders autism, tumors, and cancer are also included.\n\nCannabis products have been consumed in various forms for thousands of years. The first descriptions of the medical uses date from Chinese herbal texts in the first century A.D. Cannabis products were taken orally in an herbal tea concoction and were used for their pain-relieving and sleep-inducing properties.\n\nThere presently exists the need to provide more effective and safer cannabis extracts for various medical uses, extraction methods that provide unique active compounds that are useful to treat pain and various medical conditions. Additionally, presently known extraction procedures do not provide the desired active ingredient(s) for the particular medical purpose. The present invention overcomes these limitations and provides other related advantages.\n\nThe invention provides an extract comprising a mixture of at least 95% total cannabinoids, and at least one terpene/flavonoid. The extract contains at least 4, 5, 6, 7 or more cannabinoids. The cannabinoids are selected from tetrahydrocannabinolic acid (THCa), cannabidiolic acid (CBDa), cannabinolic acid (CBNa) cannabichromenic acid (CBCa), tetrahydrocannabinol (THC), cannabinol (CBN), cannabidiol (CBD) or cannabichromene (CBC).",
  "cpc": [
    "A61K 31/353",
    "A61K 2236/17",
    "A61K 2236/31",
    "A61K 2236/33",
    "A61K 2236/37",
    "A61K 2236/53",
    "A61K 31/05",
    "A61K 31/192",
    "A61K 31/352",
    "A61K 31/658",
    "A61K 36/185",
    "A61K 36/3482",
    "A61K 36/60",
    "A61K 36/752",
    "A61K 9/0053",
    "A61K 9/006",
    "A61P 1/00",
    "A61P 1/04",
    "A61P 25/00",
    "A61P 25/04",
    "A61P 25/08",
    "A61P 25/18",
    "A61P 25/22",
    "A61P 25/36",
    "A61P 27/06",
    "A61P 29/00",
    "A61P 35/00",
    "A61P 43/00"
  ],
  "ipc": [
    "A61K 31/05",
    "A61K 31/192",
    "A61K 31/352",
    "A61K 31/353",
    "A61K 36/185",
    "A61K 31/35"
  ],
  "assignees": [
    "United Cannabis Corp"
  ],
  "inventors": [
    "Tony Verzura",
    "Earnie Blackmon"
  ],
  "filing_date": "2015-10-21",
  "publication_date": "2017-08-15",
  "grant_date": "2017-08-15",
  "priority_date": "2014-10-21",
  "application_number": "US-201514919245-A",
  "family_id": "54477280",
  "cited_by_count": 107,
  "citations": [
    "US6949582B1",
    "DE10051427C1",
    "US20030050334A1",
    "CA2503310A1",
    "US20110092583A1",
    "GB2434312A",
    "EP2182940A1",
    "US20130059018A1",
    "US20120264818A1",
    "US20140271940A1"
  ]
}